Identifying novel genetic variants for brain amyloid deposition: a genome-wide association study in the Korean population

[1]  K. Lunetta,et al.  Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel: A Meta-analysis. , 2020, JAMA neurology.

[2]  Sterling C. Johnson,et al.  Association Between Common Variants in RBFOX1, an RNA-Binding Protein, and Brain Amyloidosis in Early and Preclinical Alzheimer Disease. , 2020, JAMA neurology.

[3]  Young Hee Jung,et al.  The Cortical Neuroanatomy Related to Specific Neuropsychological Deficits in Alzheimer's Continuum , 2019, Dementia and neurocognitive disorders.

[4]  Alicia R. Martin,et al.  Clinical use of current polygenic risk scores may exacerbate health disparities , 2019, Nature Genetics.

[5]  D. Y. Lee,et al.  Clinical and Biomarker Characteristics According to Clinical Spectrum of Alzheimer’s Disease (AD) in the Validation Cohort of Korean Brain Aging Study for the Early Diagnosis and Prediction of AD , 2019, Journal of clinical medicine.

[6]  Nick C Fox,et al.  Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing , 2019, Nature Genetics.

[7]  R. Davis,et al.  FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation , 2019, Nature Communications.

[8]  Timothy J. Hohman,et al.  Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk , 2019, Nature Genetics.

[9]  A. Saykin,et al.  Genome-wide association study of brain amyloid deposition as measured by Pittsburgh Compound-B (PiB)-PET imaging , 2018, Molecular Psychiatry.

[10]  T. Tsunoda,et al.  Sample Size for Successful Genome-Wide Association Study of Major Depressive Disorder , 2018, Front. Genet..

[11]  C. Jack,et al.  NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.

[12]  M. Kunitski,et al.  Double-slit photoelectron interference in strong-field ionization of the neon dimer , 2018, Nature Communications.

[13]  Kwangsik Nho,et al.  Associations of the Top 20 Alzheimer Disease Risk Variants With Brain Amyloidosis , 2018, JAMA neurology.

[14]  R. Kessler,et al.  Genome-wide Analysis of Insomnia Disorder , 2018, Molecular Psychiatry.

[15]  Henrik Zetterberg,et al.  Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity , 2017, Nature Communications.

[16]  A. Fleisher,et al.  Performance of [18F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease , 2017, Alzheimer's & dementia.

[17]  John Seibyl,et al.  Optimized classification of 18F-Florbetaben PET scans as positive and negative using an SUVR quantitative approach and comparison to visual assessment , 2017, NeuroImage: Clinical.

[18]  M. Weiner,et al.  The crisis in recruitment for clinical trials in Alzheimer's and dementia: An action plan for solutions , 2016, Alzheimer's & Dementia.

[19]  S. Fullerton,et al.  Genomics is failing on diversity , 2016, Nature.

[20]  D. Goldstein,et al.  Unequal representation of genetic variation across ancestry groups creates healthcare inequality in the application of precision medicine , 2016, Genome Biology.

[21]  Latarsha J. Carithers,et al.  The Genotype-Tissue Expression (GTEx) Project. , 2015, Biopreservation and biobanking.

[22]  Li Shen,et al.  GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer's disease implicates microglial activation gene IL1RAP. , 2015, Brain : a journal of neurology.

[23]  Gabor T. Marth,et al.  A global reference for human genetic variation , 2015, Nature.

[24]  Andrew J. Saykin,et al.  Genetic Interactions Explain Variance in Cingulate Amyloid Burden: An AV-45 PET Genome-Wide Association and Interaction Study in the ADNI Cohort , 2015, BioMed research international.

[25]  A. Heimberger,et al.  FGL2 as a Multimodality Regulator of Tumor-Mediated Immune Suppression and Therapeutic Target in Gliomas. , 2015, Journal of the National Cancer Institute.

[26]  John Seibyl,et al.  Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study , 2015, Alzheimer's & Dementia.

[27]  I. Cherny,et al.  The cell-membrane prothrombinase, fibrinogen-like protein 2, promotes angiogenesis and tumor development. , 2015, Thrombosis research.

[28]  Ranjan Duara,et al.  Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. , 2015, JAMA neurology.

[29]  Gonçalo R. Abecasis,et al.  Minimac2: Faster Genotype Imputation , 2015, Bioinform..

[30]  Yi-Min Sun,et al.  Associations between apolipoprotein E gene polymorphisms and Alzheimer’s disease risk in a large Chinese Han population , 2015, Clinical interventions in aging.

[31]  Y. Li,et al.  Trans-ethnic genome-wide association studies: advantages and challenges of mapping in diverse populations , 2014, Genome Medicine.

[32]  Lennart Thurfjell,et al.  Automated Quantification of 18F-Flutemetamol PET Activity for Categorizing Scans as Negative or Positive for Brain Amyloid: Concordance with Visual Image Reads , 2014, The Journal of Nuclear Medicine.

[33]  C. Carlson,et al.  Generalization and Dilution of Association Results from European GWAS in Populations of Non-European Ancestry: The PAGE Study , 2013, PLoS biology.

[34]  Ellen T. Gelfand,et al.  The Genotype-Tissue Expression (GTEx) project , 2013, Nature Genetics.

[35]  C. Jack,et al.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.

[36]  Michael W. Weiner,et al.  APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study , 2013, Molecular Psychiatry.

[37]  J. Marchini,et al.  Fast and accurate genotype imputation in genome-wide association studies through pre-phasing , 2012, Nature Genetics.

[38]  R. Petersen.  Clinical practice. Mild cognitive impairment. , 2011, The New England journal of medicine.

[39]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[40]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[41]  B. Stranger,et al.  Progress and Promise of Genome-Wide Association Studies for Human Complex Trait Genetics , 2011, Genetics.

[42]  E. Salmon,et al.  18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial , 2010, Annals of neurology.

[43]  C. Rotimi,et al.  Genetic Variants Associated with Complex Human Diseases Show Wide Variation across Multiple Populations , 2009, Public Health Genomics.

[44]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[45]  L. Lue,et al.  Gene expression changes by amyloid β peptide‐stimulated human postmortem brain microglia identify activation of multiple inflammatory processes , 2006, Journal of leukocyte biology.

[46]  L. Fratiglioni,et al.  Role of genes and environments for explaining Alzheimer disease. , 2006, Archives of general psychiatry.

[47]  P. Whitehouse,et al.  Mild cognitive impairment , 2006, Lancet.

[48]  Masatoshi Takeda,et al.  Identification of hippocampus‐related candidate genes for Alzheimer's disease , 2005, Annals of neurology.

[49]  Ki Woong Kim,et al.  A normative study of the CERAD neuropsychological assessment battery in the Korean elderly , 2004, Journal of the International Neuropsychological Society.

[50]  O. Rotstein,et al.  Soluble Fibrinogen-Like Protein 2/Fibroleukin Exhibits Immunosuppressive Properties: Suppressing T Cell Proliferation and Inhibiting Maturation of Bone Marrow-Derived Dendritic Cells1 , 2003, The Journal of Immunology.

[51]  L. Wasserman,et al.  Genomic control, a new approach to genetic-based association studies. , 2001, Theoretical population biology.

[52]  J. Marshall,et al.  Murine Hepatitis Virus Strain 3 Induces the Macrophage Prothrombinase fgl-2 through p38 Mitogen-activated Protein Kinase Activation* , 1998, The Journal of Biological Chemistry.

[53]  J. Haines,et al.  Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis , 1997 .

[54]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..